Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AiLife International Group Limited
愛生命國際集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 784)

PROFIT WARNING

This announcement is made by AiLife International Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, according to the information currently available and after a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2026 (the "**Period**") by the management of the Company, the Group expects to record a loss attributable to the equity holders of the Company for the Period of approximately HK$5.9 million, as compared to the profit attributable to the equity holders of the Company for the six months ended 30 September 2025 of approximately HK$0.3 million, primarily due to (i) the Group's acceptance of projects at lower tender prices and reduced profit margins in order to maintain business amid the economic downturn in the construction industry during the Period; (ii) the one-off sale of waste material during the six months ended 30 September 2025 which is non-recurring during the Period; and (iii) the one-off legal and professional fees incurred in connection with the unconditional mandatory cash offer as disclosed in the composite document dated 5 May 2026 and jointly issued by Hapbiotech Investment Holding Limited as offeror and the Company, which was closed during the Period.

The Company is still in the process of finalizing the results of the Group for the Period. The information contained in this announcement is only based on the preliminary assessment of the information currently available to the Board as at the date of this announcement, as well as the preliminary assessment made with reference to the unaudited consolidated management accounts for the Period (such accounts have not been confirmed, reviewed or audited by the Company's auditor nor reviewed by the audit committee of the Company, and may therefore be subject to adjustments and may differ from the Group's unaudited interim results) currently available to the management and other information currently available. The unaudited interim results of the Group for the Period are expected to be published by the end of November 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
AiLife International Group Limited
Xu Mingyan
Chairman and Executive Director

Hong Kong, 17 November 2026

As at the date of this announcement, the Board comprises Dr. Xu Mingyan, Dr. Chen Shifu and Ms. Wen Yuan as executive Directors and Mr. Wu Di, Mr. Gong Weixing and Dr. Tang Yongjun as independent nonexecutive Directors.